LIVIA Group has entered an agreement to acquire the Capua manufacturing facility and associated employees from Patheon.

Capua, one of the world’s largest independent microbial fermentation-based manufacturing facilities with 1,400m³ fermentor capacity, represents an investment opportunity for LIVIA in the attractive market of enzymes and small molecules.

LIVIA Group founder professor Dr Peter Löw said: "LIVIA Group is enthusiastic about working with Capua to build on their existing strong market position through a focus on product development, a revitalised sales function and improved production efficiency.

"We are very pleased to be invested in the business and look forward to supporting its future growth."

Capua delivers enzymes, therapeutic proteins and high-value small molecules for applications in the food, feed, pharma, agrochemical and fine chemical industries.

The facility is both FDA and EMEA (Pharma cGMP) approved. It is ISO: 14001 certified and serves customers in more than 60 countries.

In addition to its regular production, Capua offers pilot plant capabilities for customised product development, process scale-up and validation.

Patheon president drug substance services Lukas Utiger said: "We are very pleased to find a buyer for the Capua facility that is focused on servicing existing customers and adding new ones.

"Selling the Capua site is part of Patheon’s efforts to focus its core business strategy as a leading global provider of outsourced, end-to-end pharmaceutical development and manufacturing services.

"We elected to sell the operations to LIVIA Group, who is very focused on growing the operations and continuing to provide a positive work environment for employees."